^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    dacarbazine

    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    3d
    A Phase II Trial of LM103 in Advanced Melanoma (clinicaltrials.gov)
    P2, N=92, Recruiting, Suzhou BlueHorse Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF mutation • NRAS mutation • BRAF V600
    |
    cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • LM103
    7d
    ECHELON-1 : A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P3, N=1334, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • bleomycin • vinblastine
    7d
    A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) (clinicaltrials.gov)
    P3, N=78, Active, not recruiting, Erasca, Inc. | Recruiting --> Active, not recruiting | N=470 --> 78
    Enrollment closed • Enrollment change
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Mekinist (trametinib) • temozolomide • dacarbazine • naporafenib (ERAS-254)
    10d
    Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov)
    P3, N=325, Recruiting, Advenchen Laboratories, LLC | Active, not recruiting --> Recruiting | Trial completion date: Jun 2025 --> Dec 2028 | Trial primary completion date: Dec 2024 --> Dec 2027
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Focus V (anlotinib) • dacarbazine • midazolam hydrochloride
    11d
    A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India (clinicaltrials.gov)
    P4, N=124, Recruiting, Takeda | Trial completion date: Mar 2026 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride • Adcetris (brentuximab vedotin) • dacarbazine • vinblastine
    15d
    Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) (clinicaltrials.gov)
    P2, N=340, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Nov 2026 | Trial primary completion date: Feb 2027 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • dacarbazine • bleomycin • vinblastine
    17d
    CA209-447: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL) (clinicaltrials.gov)
    P1/2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • doxorubicin hydrochloride • dacarbazine • bleomycin • vinblastine
    17d
    DAR-UM-2: IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (clinicaltrials.gov)
    P2/3, N=420, Active, not recruiting, IDEAYA Biosciences | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Xalkori (crizotinib) • Yervoy (ipilimumab) • dacarbazine • darovasertib (IDE196)
    17d
    GCO-003 TARLANEC: Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine carcinomas (NECs) (2024-515948-23-00)
    P2/3, N=129, Recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P2/3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    DLL3 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • docetaxel • 5-fluorouracil • temozolomide • irinotecan • dacarbazine • topotecan • Imdelltra (tarlatamab-dlle)
    17d
    Uni-Koeln-4938: Pembro-FLASH (2022-501458-13-01)
    P1/2, N=40, Not yet recruiting, University Of Cologne
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • Adcetris (brentuximab vedotin) • dacarbazine
    24d
    Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery (clinicaltrials.gov)
    P2, N=220, Recruiting, The First Hospital of Jilin University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    cisplatin • Tyvyt (sintilimab) • temozolomide • dacarbazine
    25d
    PROMIT: Preconditioning of Tumor, Tumor Microenvironment and the Immune System to Immunotherapy (clinicaltrials.gov)
    P2, N=38, Completed, University of Erlangen-Nürnberg Medical School | Recruiting --> Completed | Trial completion date: Jul 2023 --> Jan 2026 | Trial primary completion date: Jun 2023 --> Jan 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    dacarbazine